C4 Therapeutics (CCCC)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	62.25 mm	62.25 mm	62.25 mm	62.25 mm	62.25 mm	62.25 mm
Cash burn (monthly)	6.45 mm	70.00 k	11.47 mm	10.82 mm	10.40 mm	7.87 mm
Cash used (since last report)	23.58 mm	255.89 k	41.93 mm	39.54 mm	38.03 mm	28.78 mm
Cash remaining	38.68 mm	62.00 mm	20.32 mm	22.71 mm	24.23 mm	33.47 mm
Runway (months of cash)	6.0	885.7	1.8	2.1	2.3	4.3

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q4 2024

CCCC institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	117	123	-4.9%
Opened positions	26	34	-23.5%
Closed positions	32	28	+14.3%
Increased positions	38	38	–
Reduced positions	33	30	+10.0%

13F shares	Current	Prev Q	Change
Total value	230.83 bn	360.77 bn	-36.0%
Total shares	76.56 mm	76.35 mm	+0.3%
Total puts	114.70 k	54.80 k	+109.3%
Total calls	651.30 k	669.50 k	-2.7%
Total put/call ratio	0.2	0.1	+115.2%

Largest owners	Shares	Value	Change
Soleus Capital Management	6.98 mm	$25.12 bn	+5.7%
Lynx1 Capital Management	6.85 mm	$24.67 bn	-0.4%
Soleus Capital Master Fund	6.60 mm	$36.52 mm	0.0%
Wasatch Advisors	6.07 mm	$21.86 bn	+7.0%
Betta Investment	5.57 mm	$35.30 mm	0.0%
BLK BlackRock	5.56 mm	$20.01 bn	+13.7%
Ra Capital Management	4.88 mm	$17.56 bn	0.0%
Orbimed Advisors	4.38 mm	$15.76 bn	0.0%
MS Morgan Stanley	3.84 mm	$13.82 bn	+65.1%
Vanguard	3.35 mm	$12.05 bn	-0.7%

Largest transactions	Shares	Bought/sold	Change
Commodore Capital	0.00	-3.41 mm	EXIT
Samlyn Capital	3.02 mm	+3.02 mm	NEW
STT State Street	1.22 mm	-1.58 mm	-56.4%
MS Morgan Stanley	3.84 mm	+1.51 mm	+65.1%
Adage Capital Partners GP, L.L.C.	1.55 mm	+1.03 mm	+198.1%
Point72 Asset Management	196.47 k	-1.01 mm	-83.7%
BLK BlackRock	5.56 mm	+667.92 k	+13.7%
UBS UBS	757.85 k	+423.77 k	+126.8%
Wasatch Advisors	6.07 mm	+395.23 k	+7.0%
Soleus Capital Management	6.98 mm	+374.95 k	+5.7%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

CCCC insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
16 Jan 26	Leonard Reyno	Common Stock	Sell	Dispose S	No	No	2.22	10,000	22.20 k	156,382
2 Jan 26	Grogan Donna Roy	Common Stock	Grant	Acquire A	No	No	1.93	7,513	14.50 k	66,142
2 Jan 26	Kenneth Carl Anderson	Common Stock	Grant	Acquire A	No	No	1.93	5,958	11.50 k	146,532
28 Oct 25	Paige Mahaney	Common Stock	Payment of exercise	Dispose F	No	No	2.58	5,644	14.56 k	99,356
28 Oct 25	Paige Mahaney	Common Stock	Option exercise	Acquire M	No	No	0	19,200	0.00	105,000
1 Oct 25	Kenneth Carl Anderson	Common Stock	Grant	Acquire A	No	No	2.15	5,349	11.50 k	140,574

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

C4 Therapeutics Positions Cemsidomide As Potential Best-In-Class Myeloma Therapy While Expanding Discovery Efforts Beyond Oncology

14 Jan 26

Cemsidomide Phase 2 MOMENTUM Trial On Track to Initiate in Q1 2026; Recommended Phase 2 Dose is 100 µgCemsidomide Phase 1b Trial in Combination With Elranatamab On Track to Initiate in Q2 2026Internal Discovery

Barclays Maintains Overweight on C4 Therapeutics, Lowers Price Target to $5

17 Dec 25

Barclays analyst Etzer Darout maintains C4 Therapeutics (NASDAQ:CCCC) with a Overweight and lowers the price target from $10 to $5.

This Coca-Cola Femsa Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Tuesday

2 Dec 25

This Cloudflare Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

2 Dec 25

TD Cowen Initiates Coverage On C4 Therapeutics with Buy Rating

2 Dec 25